Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy AbCellera Biologics (ABCL) shares

Learn how to easily invest in AbCellera Biologics shares.

AbCellera Biologics is a biotechnology business based in the US. AbCellera Biologics stocks (ABCL.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $23.53 – a decrease of 13.99% over the previous week. AbCellera Biologics employs 360 staff and has a trailing 12-month revenue of around $443.8 million.

How to buy shares in AbCellera Biologics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ABCL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

AbCellera Biologics stock price (NASDAQ:ABCL)

Use our graph to track the performance of ABCL stocks over time.

AbCellera Biologics shares at a glance

Information last updated 2022-01-25.
Latest market close$7.81
52-week range$7.42 - $55.22
50-day moving average $13.62
200-day moving average $19.24
Wall St. target price$38.88
PE ratio 13.3075
Dividend yield N/A (0%)
Earnings per share (TTM) $0.64

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy AbCellera Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

AbCellera Biologics price performance over time

Historical closes compared with the close of $7.81 from 2022-01-26

1 week (2022-01-21) -9.61%
1 month (2021-12-28) -43.03%
3 months (2021-10-28) -50.94%
6 months (2021-07-28) -51.43%
1 year (2021-01-28) -84.83%
2 years (2020-01-24) N/A
3 years (2019-01-24) N/A
5 years (2017-01-24) N/A

Is AbCellera Biologics under- or over-valued?

Valuing AbCellera Biologics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AbCellera Biologics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AbCellera Biologics's P/E ratio

AbCellera Biologics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, AbCellera Biologics shares trade at around 13x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

AbCellera Biologics's EBITDA

AbCellera Biologics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $298.5 million.

The EBITDA is a measure of a AbCellera Biologics's overall financial performance and is widely used to measure a its profitability.

AbCellera Biologics financials

Revenue TTM $443.8 million
Operating margin TTM 64.34%
Gross profit TTM $176.6 million
Return on assets TTM 27.14%
Return on equity TTM 40.38%
Profit margin 47.44%
Book value $3.39
Market capitalisation $2.4 billion

TTM: trailing 12 months

AbCellera Biologics share dividends

We're not expecting AbCellera Biologics to pay a dividend over the next 12 months.

AbCellera Biologics overview

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are either completed, in progress, or under contract. It has a discovery partnership agreement with Eli Lilly and Company. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site